Pip: Nutrition.Hauora.NZ is asking whether what you eat could change how your brain behaves — and not in the vague wellness-influencer sense, but with citations.
Mara: Today’s episode comes from nutritionhauoranz, and it goes deep on the ketogenic diet as a potential tool for managing bipolar disorder — the mechanisms, the caveats, and what the current evidence actually supports. Let’s start with what the science says about ketosis and mental health.
Ketogenic Diet and Bipolar Disorder: What the Evidence Says
Pip: The question at the center of this post is whether a high-fat, very low carbohydrate diet could do something useful for a condition that psychiatry has mostly approached with pharmaceuticals — and whether the brain-energy angle gives us a real mechanism or just a compelling story.
Mara: The post sets up the mechanism clearly. Elevated brain ketones are proposed to stabilize mood and enhance mitochondrial function, and the post states directly: “Issues with neuronal energy metabolism and oxidative stress are features in the pathophysiology of mental health and neurodegenerative disorders, including bipolar disorder; both of which are shown to have been improved by the Ketogenic Diet.”
Pip: So the argument isn’t just that keto makes you feel better in some general sense — it’s that bipolar disorder involves specific metabolic dysfunctions, and ketosis addresses those dysfunctions through identifiable pathways.
Mara: Right. The post walks through several of those pathways: GABA upregulation, inhibition of excitatory neurons, and the anti-inflammatory effects of beta-hydroxybutyrate — including suppression of the NLRP3 inflammasome and reduction of reactive oxygen species. It also flags neuroprotective effects, including protection of the blood-brain barrier.
Pip: That is a lot of moving parts — which is either reassuring or a sign that the mechanism story is being assembled post-hoc from a lot of separate literatures.
Mara: The post is honest about that tension. A case series by Palmer et al. reported patients with bipolar disorder showing notable reductions in mood instability, with some experiencing full remission. A small pilot study showed reduced reliance on psychiatric medications. But the post is explicit that large-scale randomized controlled trials are still missing.
Mara: On side effects, the post covers the keto flu, uric acid elevation, kidney stone risk, and the cholesterol picture — citing the Budoff KETO Trial, which tracked lean mass hyper-responders for a mean of 4.7 years and found no measurable increase in atherosclerosis despite elevated LDL.
Pip: There’s also a methodological flag worth naming: a meta-analysis the post reviews defined “low carbohydrate” as under 45 percent of calories from carbs — which is nowhere near ketogenic — so its null finding on anxiety and depression doesn’t really test the hypothesis being made here.
Mara: That’s one of the post’s sharper observations. Without measuring actual ketone levels in participants, you cannot confirm they were in nutritional ketosis, and diet quality wasn’t controlled either. The post concludes that the ketogenic diet shows genuine promise as an adjunctive approach, particularly for patients who haven’t responded to standard pharmaceutical treatment, while calling clearly for more rigorous clinical data.
Pip: The honest summary of where the evidence sits right now — promising mechanisms, early clinical signals, and a research gap that still needs filling.
Mara: The through-line today is that metabolic interventions can reach into territory we usually reserve for pharmacology — and the evidence is early but not negligible.
Pip: Next time, bring your appetite for mechanism. There’s more ground to cover here.
Nutrition Hauora NZ 